{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T06:40:54Z","timestamp":1775630454643,"version":"3.50.1"},"reference-count":34,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/jtxh6594","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T01:50:46Z","timestamp":1752112246000},"page":"4701-4712","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of inflammatory protein expression patterns and their association with viral DNA load in hepatitis B virus infection via Olink proteomics analysis"],"prefix":"10.62347","volume":"17","author":[{"given":"Xiangjuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3350\/cmh.2023.0412","article-title":"Comprehensive approach to controlling chronic hepatitis B in China","volume":"30","author":"Shan","year":"2024","unstructured":"Shan S, Zhao X and Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clin Mol Hepatol 2024; 30: 135-143.","journal-title":"Clin Mol Hepatol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cld.2022.08.001","article-title":"Chronic hepatitis B virus and hepatitis D virus: new developments","volume":"27","author":"Robinson","year":"2023","unstructured":"Robinson A, Wong R and Gish RG. Chronic hepatitis B virus and hepatitis D virus: new developments. Clin Liver Dis 2023; 27: 17-25.","journal-title":"Clin Liver Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/v15040997","article-title":"Evidence for benefits of early treatment initiation for chronic hepatitis B","volume":"15","author":"Lim","year":"2023","unstructured":"Lim YS, Kim WR, Dieterich D, Kao JH, Flaherty JF, Yee LJ, Roberts LR, Razavi H and Kennedy PTF. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses 2023; 15: 997.","journal-title":"Viruses"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"156442","DOI":"10.1016\/j.cyto.2023.156442","article-title":"Cytokine profiles and virological markers highlight distinctive immune statuses, and effectivenesses and limitations of NAs across different courses of chronic HBV infection","volume":"173","author":"Xiao","year":"2024","unstructured":"Xiao L, Tang K, Fu T, Yuan X, Seery S, Zhang W, Ji Z, He Z, Yang Y, Zhang W, Jia W, Liang C, Tang H, Wang F, Ye Y, Chen L and Shao Z. Cytokine profiles and virological markers highlight distinctive immune statuses, and effectivenesses and limitations of NAs across different courses of chronic HBV infection. Cytokine 2024; 173: 156442.","journal-title":"Cytokine"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Dai L, Yan Y and Chen Q. Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis. Medicine (Baltimore) 2024; 103: e38342.","DOI":"10.1097\/MD.0000000000038342"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.3390\/cancers12102967","article-title":"Chemerin is induced in non-alcoholic fatty liver disease and hepatitis B-related hepatocellular carcinoma","volume":"12","author":"EM","year":"2020","unstructured":"Haberl EM, Feder S, Pohl R, Rein-Fischboeck L, Dürholz K, Eichelberger L, Wanninger J, Weiss TS and Buechler C. Chemerin is induced in non-alcoholic fatty liver disease and hepatitis B-related hepatocellular carcinoma. Cancers (Basel) 2020; 12: 2967.","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jvh.13905","article-title":"Serum CXCL16: a new predictor of liver inflammation in patients with chronic hepatitis B","volume":"31","author":"Wan","year":"2024","unstructured":"Wan Y, Mao M, Li M, Liu J, Tong X, Wang J, Li J, Yin S and Wu C. Serum CXCL16: a new predictor of liver inflammation in patients with chronic hepatitis B. J Viral Hepat 2024; 31: 107-119.","journal-title":"J Viral Hepat"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/v12080864","article-title":"Chronic hepatitis B infection is associated with increased molecular degree of inflammatory perturbation in peripheral blood","volume":"12","author":"Vinhaes","year":"2020","unstructured":"Vinhaes CL, Cruz LAB, Menezes RC, Carmo TA, Arriaga MB, Queiroz ATL, Barral-Netto M and Andrade BB. Chronic hepatitis B infection is associated with increased molecular degree of inflammatory perturbation in peripheral blood. Viruses 2020; 12: 864.","journal-title":"Viruses"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1241199","DOI":"10.3389\/fimmu.2023.1241199","article-title":"Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay","volume":"14","author":"Kmezic","year":"2023","unstructured":"Kmezic I, Gustafsson R, Fink K, Svenningsson A, Samuelsson K, Ingre C, Olsson T, Hansson M, Kockum I, Adzemovic MZ and Press R. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay. Front Immunol 2023; 14: 1241199.","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-023-01631-6","article-title":"Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study","volume":"25","author":"FB","year":"2023","unstructured":"Gunnarsdottir FB, Bendahl PO, Johansson A, Benfeitas R, Rydén L, Bergenfelz C and Larsson AM. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study. Breast Cancer Res 2023; 25: 29.","journal-title":"Breast Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.mcpro.2023.100577","article-title":"MS-based proteomics of body fluids: the end of the beginning","volume":"22","author":"JM","year":"2023","unstructured":"Bader JM, Albrecht V and Mann M. MS-based proteomics of body fluids: the end of the beginning. Mol Cell Proteomics 2023; 22: 100577.","journal-title":"Mol Cell Proteomics"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Taleb S, Stephan N, Chennakkandathil S, Sohail MU, Yousef S, Sarwath H, Al-Noubi M, Suhre K, Ait Hssain A and Schmidt F. Comparative analysis between Olink-PEA and Alamar-NULISA proteomic technologies applied to a critically Ill COVID-19 cohort. Proteomics 2025; e202400456.","DOI":"10.1002\/pmic.202400456"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","article-title":"Multiplatform approach for plasma proteomics: complementarity of Olink proximity extension assay technology to mass spectrometry-based protein profiling","volume":"20","author":"Petrera","year":"2021","unstructured":"Petrera A, von Toerne C, Behler J, Huth C, Thorand B, Hilgendorff A and Hauck SM. Multiplatform approach for plasma proteomics: complementarity of Olink proximity extension assay technology to mass spectrometry-based protein profiling. J Proteome Res 2021; 20: 751-762.","journal-title":"J Proteome Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1021\/acs.jproteome.4c00522","article-title":"Plasma Olink proteomics reveals novel biomarkers for prediction and diagnosis in dilated cardiomyopathy with heart failure","volume":"23","author":"Xu","year":"2024","unstructured":"Xu S, Zhang G, Tan X, Zeng Y, Jiang H, Jiang Y, Wang X, Song Y, Fan H and Zhou Y. Plasma Olink proteomics reveals novel biomarkers for prediction and diagnosis in dilated cardiomyopathy with heart failure. J Proteome Res 2024; 23: 4139-4150.","journal-title":"J Proteome Res"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.13470","article-title":"HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma","volume":"201","author":"Zhao","year":"2020","unstructured":"Zhao L, Jin Y, Yang C and Li C. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma. Clin Exp Immunol 2020; 201: 289-296.","journal-title":"Clin Exp Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/HEP.0000000000000300","article-title":"Plasma proteomic signature of fatty liver disease: the Rotterdam study","volume":"78","author":"Abozaid","year":"2023","unstructured":"Abozaid YJ, Ayada I, van Kleef LA, Vallerga CL, Pan Q, Brouwer WP, Ikram MA, Van Meurs J, de Knegt RJ and Ghanbari M. Plasma proteomic signature of fatty liver disease: the Rotterdam study. Hepatology 2023; 78: 284-294.","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.hbpd.2023.10.006","article-title":"Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma","volume":"23","author":"KT","year":"2024","unstructured":"Ng KT, Pang L, Wang JQ, She WH, Tsang SH, Lo CM, Man K and Cheung TT. Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2024; 23: 257-264.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/jgh.14617","article-title":"The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection","volume":"34","author":"Townsend","year":"2019","unstructured":"Townsend EC, Zhang GY, Ali R, Firke M, Moon MS, Han MAT, Fram B, Glenn JS, Kleiner DE, Koh C and Heller T. The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. J Gastroenterol Hepatol 2019; 34: 764-775.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.14218\/JCTH.2021.00160","article-title":"Change of cytokines in chronic hepatitis B patients and HBeAg are positively correlated with HBV RNA, based on real-world study","volume":"10","author":"Zhang","year":"2022","unstructured":"Zhang Q, Huang H, Sun A, Liu C, Wang Z, Shi F, Duan W, Sun X, Wang Q, Sun P, Pu C and Zhang Y. Change of cytokines in chronic hepatitis B patients and HBeAg are positively correlated with HBV RNA, based on real-world study. J Clin Transl Hepatol 2022; 10: 390-397.","journal-title":"J Clin Transl Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"116635","DOI":"10.1016\/j.taap.2023.116635","article-title":"Serum levels of IL-6\/IL-10\/GLDH may be early recognition markers of anti-tuberculosis drugs (ATB) -induced liver injury","volume":"475","author":"Xiang","year":"2023","unstructured":"Xiang HR, Li Y, Cheng X, He B, Li HM, Zhang QZ, Wang B and Peng WX. Serum levels of IL-6\/IL-10\/GLDH may be early recognition markers of anti-tuberculosis drugs (ATB) -induced liver injury. Toxicol Appl Pharmacol 2023; 475: 116635.","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3390\/ijms19061766","article-title":"IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies","volume":"19","author":"Loosen","year":"2018","unstructured":"Loosen SH, Schulze-Hagen M, Leyh C, Benz F, Vucur M, Kuhl C, Trautwein C, Tacke F, Bruners P, Roderburg C and Luedde T. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci 2018; 19: 1766.","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2147\/JIR.S302975","article-title":"Study of the expression of inflammatory factors IL-4, IL-6, IL-10, and IL-17 in liver failure complicated by coagulation dysfunction and sepsis","volume":"14","author":"Li","year":"2021","unstructured":"Li L, Chen L, Lin F, Mu J, Wang D, Zhang W, Mi L, Qin Y and Zhou Y. Study of the expression of inflammatory factors IL-4, IL-6, IL-10, and IL-17 in liver failure complicated by coagulation dysfunction and sepsis. J Inflamm Res 2021; 14: 1447-1453.","journal-title":"J Inflamm Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13027-024-00580-9","article-title":"Expression of 10 circulating cytokines\/chemokines in HBV-related liver disease","volume":"19","author":"Jia","year":"2024","unstructured":"Jia Y, Jiao X, Shi W, Luo Y, Xiang H, Liang J and Gao Y. Expression of 10 circulating cytokines\/chemokines in HBV-related liver disease. Infect Agent Cancer 2024; 19: 20.","journal-title":"Infect Agent Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2023.02.026","article-title":"Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury","volume":"79","author":"CP","year":"2023","unstructured":"Hackstein CP, Spitzer J, Symeonidis K, Horvatic H, Bedke T, Steglich B, Klein S, Assmus LM, Odainic A, Szlapa J, Kessler N, Beyer M, Schmithausen R, Latz E, Flavell RA, Garbi N, Kurts C, Kümmerer BM, Trebicka J, Roers A, Huber S, Schmidt SV, Knolle PA and Abdullah Z. Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury. J Hepatol 2023; 79: 150-166.","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1219907","DOI":"10.3389\/fimmu.2023.1219907","article-title":"TNF superfamily control of tissue remodeling and fibrosis","volume":"14","author":"Steele","year":"2023","unstructured":"Steele H, Cheng J, Willicut A, Dell G, Breckenridge J, Culberson E, Ghastine A, Tardif V and Herro R. TNF superfamily control of tissue remodeling and fibrosis. Front Immunol 2023; 14: 1219907.","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Colli A, Fraquelli M, Prati D and Casazza G. Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease. Cochrane Database Syst Rev 2023; 6: CD013532.","DOI":"10.1002\/14651858.CD013532.pub2"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"156727","DOI":"10.1016\/j.cyto.2024.156727","article-title":"Growth differentiation factor 15: emerging role in liver diseases","volume":"182","author":"Li","year":"2024","unstructured":"Li Y, Zhang J, Chen S, Ke Y, Li Y and Chen Y. Growth differentiation factor 15: emerging role in liver diseases. Cytokine 2024; 182: 156727.","journal-title":"Cytokine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3748\/wjg.v29.i16.2479","article-title":"Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication","volume":"29","author":"Jiang","year":"2023","unstructured":"Jiang SW, Lian X, Hu AR, Lu JL, He ZY, Shi XJ, Zhu DD, Wang ZY and Huang GC. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication. World J Gastroenterol 2023; 29: 2479-2494.","journal-title":"World J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12985-024-02368-0","article-title":"Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase","volume":"21","author":"Wang","year":"2024","unstructured":"Wang J, Zhu L, Zhang Z, Zhang S, Pan Y, Li Y, Cao F, Jiang C, Fan T, Xiong Y, Liu J, Chen Y, Yin S, Tong X, Zhu C, Liu X, Li J, Wu C and Huang R. Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase. Virol J 2024; 21: 127.","journal-title":"Virol J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1186\/s12879-023-08865-x","article-title":"Associations of Wnt5a expression with liver injury in chronic hepatitis B virus infection","volume":"23","author":"XF","year":"2023","unstructured":"Ji XF, Zhou Q, Wang JW, Sun F, Gao S and Wang K. Associations of Wnt5a expression with liver injury in chronic hepatitis B virus infection. BMC Infect Dis 2023; 23: 860.","journal-title":"BMC Infect Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1002\/jmv.26301","article-title":"Association of cytokines with hepatitis B virus and its antigen","volume":"92","author":"MH","year":"2020","unstructured":"Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, Lu Y, Yi W and Xie Y. Association of cytokines with hepatitis B virus and its antigen. J Med Virol 2020; 92: 3426-3435.","journal-title":"J Med Virol"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Wang J, Li Q, Qiu Y, Kitanovski S, Wang C, Zhang C, Li F, Li X, Zhang Z, Huang L, Zhang J, Hoffmann D, Lu M and Lu H. Cell-type-specific expression analysis of liver transcriptomics with clinical parameters to decipher the cause of intrahepatic inflammation in chronic hepatitis B. Imeta 2024; 3: e221.","DOI":"10.1002\/imt2.221"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jiph.2018.06.006","article-title":"Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers","volume":"12","author":"Tian","year":"2019","unstructured":"Tian ZJ, Shen Y, Li XR, Wei YN, Fan H and Ren QK. Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers. J Infect Public Health 2019; 12: 7-12.","journal-title":"J Infect Public Health"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0165407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:41Z","timestamp":1766023061000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0165407.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/jtxh6594","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}